Wilberforce Ndarawit, Charles Otieno Ochieng, David Angwenyi, Jorddy N Cruz, Cleydson B R Santos, Njogu M Kimani
Postprandial hyperglycemia, typical manifestation of Type 2 Diabetes Mellitus (T2DM), is associated with notable global morbidity and mortality. Preventing the advancement of this condition by delaying the rate of glucose absorption through inhibition of α-amylase and α-glucosidase enzymatic activities is of utmost importance. Finding a safe antidiabetic drug is essential since those that are currently on the market have drawbacks like unpleasant side effects. The current study utilized computer-aided drug design (CADD), as a quick and affordable method to find a substitute drug template that can be used to control postprandial hyperglycemia by modulating the activity of α-amylase and α-glucosidase enzymes. The Natural Products Activity and Species database (NPASS) (30,926 compounds) was screened in silico, with a focus on evaluating drug-likeness, toxicity profiles and ability to bind on a target protein. Two molecules NPC204580 (Chrotacumine C) and NPC137813 (1-O-(2-Methoxy-4-Acetylphenyl)-6-O-(E-Cinnamoyl)-Beta-D-Glucopyranoside) were identified as potential dual inhibitors for α-amylase and α-glucosidase with free binding energies of -14.46 kcal/mol and -12.58 kcal/mol for α-amylase, and -8.42 kcal/mol and -8.76 kcal/mol for α-glucosidase, respectively. The molecules showed ionic, H-bonding and hydrophobic interactions with critical amino acid residues of both enzymes. Moreover, 100 ns molecular dynamic simulations showed that both molecules are stable on the receptors' active sites based on root mean square deviation (RMSD), root mean square fluctuation (RMSF), and the Generalized Born surface area (GBSA) energy calculated. The two compounds are thus promising therapeutic agents for T2DM that merit further investigation due to their excellent binding energies, encouraging pharmacokinetics, toxicity profiles, and stability as demonstrated in simulated studies.
J Mol Biol. 2008 Jan 18;375(3):782-92
[PMID:
18036614]
Drug Discov Today Technol. 2004 Dec;1(4):337-41
[PMID:
24981612]
Biochemistry. 2002 Apr 2;41(13):4492-502
[PMID:
11914097]
Diabetes Res Clin Pract. 2019 Nov;157:107843
[PMID:
31518657]
S Afr J Bot. 2023 Nov;162:129-141
[PMID:
37840557]
Pharmaceuticals (Basel). 2023 Jan 09;16(1):
[PMID:
36678592]
J Biomol Struct Dyn. 2022 Aug;40(12):5386-5408
[PMID:
33427075]
Molecules. 2023 Jan 19;28(3):
[PMID:
36770702]
J Xenobiot. 2023 Feb 21;13(1):102-120
[PMID:
36976158]
Nucleic Acids Res. 2023 Jan 6;51(D1):D621-D628
[PMID:
36624664]
Chem Res Toxicol. 2016 Apr 18;29(4):564-616
[PMID:
26974882]
J Comput Chem. 2005 Dec;26(16):1668-88
[PMID:
16200636]
J Comput Chem. 2004 Jul 15;25(9):1157-74
[PMID:
15116359]
Pharmaceuticals (Basel). 2022 Jan 17;15(1):
[PMID:
35056163]
J Agric Food Chem. 2011 Sep 28;59(18):9756-62
[PMID:
21830826]
J Pharmacol Pharmacother. 2011 Apr;2(2):74-9
[PMID:
21772764]
Pharmaceuticals (Basel). 2024 Apr 16;17(4):
[PMID:
38675469]
Metabolism. 2005 Mar;54(3):387-90
[PMID:
15736118]
J Med Chem. 2002 Jun 6;45(12):2615-23
[PMID:
12036371]
Pharmaceuticals (Basel). 2023 Sep 06;16(9):
[PMID:
37765069]
Bioorg Med Chem Lett. 2013 Nov 1;23(21):5915-8
[PMID:
24035096]
J Med Chem. 2015 May 14;58(9):4066-72
[PMID:
25860834]
J Med Chem. 2019 Feb 28;62(4):1701-1714
[PMID:
30212196]
Nutrients. 2021 Sep 02;13(9):
[PMID:
34578968]
Curr Diab Rep. 2016 Oct;16(10):102
[PMID:
27640169]
Int J Mol Sci. 2021 Oct 29;22(21):
[PMID:
34769170]
Phys Rev B Condens Matter. 1988 Jan 15;37(2):785-789
[PMID:
9944570]
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
[PMID:
26574453]
Genes Environ. 2020 Jul 2;42:23
[PMID:
32626544]
Int J Mol Sci. 2023 May 16;24(10):
[PMID:
37240165]
Eur Heart J. 2016 May 07;37(18):1456-64
[PMID:
26715165]
Expert Opin Drug Discov. 2017 Sep;12(9):885-896
[PMID:
28644732]
Sci Rep. 2017 Mar 03;7:42717
[PMID:
28256516]
Molecules. 2021 Jan 29;26(3):
[PMID:
33573040]
Molecules. 2020 Oct 15;25(20):
[PMID:
33076254]
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
[PMID:
11259830]
PLoS One. 2015 Mar 27;10(3):e0119264
[PMID:
25816325]
Molecules. 2022 Jul 15;27(14):
[PMID:
35889399]
Biochemistry. 2008 Mar 18;47(11):3332-44
[PMID:
18284212]
Proc (Bayl Univ Med Cent). 2000 Oct;13(4):421-3
[PMID:
16389357]
Int J Mol Sci. 2022 Aug 19;23(16):
[PMID:
36012627]
Phys Chem Chem Phys. 2014 Oct 28;16(40):22035-45
[PMID:
25205360]
Pharm Res. 1992 May;9(5):663-9
[PMID:
1608900]
Life Sci. 2002 Aug 9;71(12):1405-15
[PMID:
12127161]
J Chem Inf Model. 2015 Feb 23;55(2):460-73
[PMID:
25558886]
J Biomol Struct Dyn. 2023;41(22):13383-13403
[PMID:
36744465]
J Cheminform. 2009 Jun 10;1(1):8
[PMID:
20298526]
Nutrients. 2020 May 27;12(6):
[PMID:
32471238]
Pharmacy (Basel). 2018 Jun 27;6(3):
[PMID:
29954090]
J Med Chem. 2000 Oct 19;43(21):3867-77
[PMID:
11052792]
J Nat Prod. 2009 Oct;72(10):1879-83
[PMID:
19757855]
Diabetes Mellitus, Type 2
alpha-Amylases
Glycoside Hydrolase Inhibitors
alpha-Glucosidases
Humans
Hypoglycemic Agents
Molecular Docking Simulation
Cheminformatics
Enzyme Inhibitors
Molecular Dynamics Simulation
